Skip to main content
. 2021 Oct 13;7(1):65–70. doi: 10.1089/pancan.2021.0006

FIG. 1.

FIG. 1.

KRAS pathways. All the common mutations G12D, G12V, G12C, and G12S operate through PI3K alpha, and have no effector protein to interact with the MEK inhibitors. In contrast, G12R operates through PI3K gamma and HAS an effector protein that interacts with MEK inhibitor. This interaction is augmented in the presence of gemcitabine.